Assessment phase: general information

The assessment period starts from the date of validation.

The timelines for the assessment of part I and part II are similar except:

  • in case of clinical trials involving ATMPs, the rMS can extend the assessment period by an additional 50 days for consulting with experts;
  • in case of sequential part II submission, there is no validation phase.